A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

Supportive Care in Cancer

Volumn 22, Issue 10, 2014, Pages 2677-2685

  Weaver, Andrew ^a   Love, Sharon B ^b   Larsen, Mark ^c   Shanyinde, Milensu ^b   Waters, Rachel ^b   Grainger, Lisa ^a   Shearwood, Vanessa ^a   Brooks, Claire ^c   Gibson, Oliver ^c   Young, Annie M ^d   Tarassenko, Lionel ^c  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Chemotherapy; Dose decrease; Dose increase; Managing side effects; Mobile phone technology

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEVICES; FEMALE; HUMAN; MALE; MIDDLE AGED; MOBILE PHONE; PHYSIOLOGIC MONITORING; PILOT STUDY; PROCEDURES;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL PHONES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PILOT PROJECTS;

EID: 84933040968     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2224-1     Document Type: Article

References (12)

1. Brearley S et al (2010) Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK. Eur J Cancer Care 19(4):425–433
2. Lyman GH et al (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22(21):4302–4311
3. Citron ML (2004) Dose-density in adjuvant chemotherapy for breast cancer. Cancer Investig 22(4):555–568
4. Kimmel SRM, Kimmig R, Schmid P (2007) Dose-dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol 19(1):75–81
5. Evans WE et al (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338(8):499–505
6. Department of Health (2013) NHS Improvement and Macmillan Cancer Support, Living with & beyond cancer: taking action to improve outcomes. Department of Health
7. Weaver A et al (2007) Application of mobile phone technology for managing chemotherapy-associated side effects. Ann Oncol 18:1887–1892
8. UKONS Oncology/haematology 24 hour triage rapid assessment and access tool kit. 2011. [online]. 2011 [cited 2013 01 February ]; Available from:
9. Adams R et al (2009) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100(2):251–258
10. Cassidy J et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006–2012
11. Chang H et al (2011) Adjuvant chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol 23(4):911–918
12. NCAG National chemotherapy advisory group, chemotherapy services in England: ensuring quality and safety. 2009. [online]. [Date accessed 01st February 2013]. Available from world wide web: 2009